Pfizer in Partnership with Shanghai Institutes For Biological Sciences for Drug Discovery Activities

摘要

Pfizer has teamed up with the Shanghai Institutes for Biological Sciences (SIBS) to advance health-related basic research. For the next three years, Pfizer will pump in US$500,000 research fund annually. Pfizer and SIBS will select the research projects jointly. Pfizer took pains to point out that the financial commitment supported innovation in basic research and not in just "the last mile of drug development," but from much earlier stages of exploration into basic healthcare principles as Mr Jeff Kindler, Pfizer's CEO, put it. The partnership is an implicit validation of China's innovation in basic science as well, in addition to Pfizer's high regard for the scientific expertise and capabilities of SIBS. China is increasingly seen as a source forinnovative healthcare research.